Clinical Trial Search

Primary: Percentage of Subjects Who Correctly Answered a Knowledge Assessment Item Immediately Before and After an Educational Lecture — 52; 94; 19; 90 percentage of participants

Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale

Primary: Cutaneous Lupus Area and Severity Index (CLASI) — 21.4; 10.8; 8.6; 5.3 units on a scale

Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants

Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037

Primary: Change in Percentage of UVB-induced Apoptotic Epidermal Cells — 20.06; 3.03; -17.03 percentage of epidermal cells

Primary: Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12 — -37.05; -42.76 percent change

Primary: Cutaneous LE Diseases Area and Severity Index (CLASI) Score Based on Extent of Symptoms

Primary: Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. — 22.2; 27.8 percentage of subjects

Primary: Mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Improvement Compared to Placebo. — -6.2; -6.5; -6.2; -5.7 Scores on a scale — p=0.845

Primary: Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS) — 100; 94; 84; 94 Percent of Baseline

Primary: Mean Severity of Disease as Measured by the Investigator's Global Assessment — 1.4 score on a scale

Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…

Primary: Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 — -4.5; -8.7; -5.5 score on a scale — p=0.7500

Primary: Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24 — 59.9; 39.2; 40.1 Percentage of participants — p=0.076

Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants

Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale

Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…

Primary: Relapse-free Complete Clinical Response — 54 Months

Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec

Primary: The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3…

Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 7; 5; 5; 7 Participants

Primary: Communication With Physician - Stanford 3Q Scale Score — 3.1; 2.9; 3.3; 3.0 score on a scale

Primary: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks — 3; 4 Participants

Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants

Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase — 5; 7; 7; 8 Participants

Primary: Number of Treatment Emergent Adverse Events — 0; 17; 2; 4 Participants

Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale

Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72